Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Neuroendocrine Tumors 40 Gastro-enteropancreatic neuroendocrine tumor 8 Paraganglioma 6 Meningioma 6 Pheochromocytoma 5 Carcinoma, Neuroendocrine 4 Neuroblastoma 3 Carcinoid Tumor 3 Adenoma, Islet Cell 3 Prostatic Neoplasms 2 Pancreatic Neoplasms 2 Neoplasms, Germ Cell and Embryonal 2 Neoplasms 2 Medulloblastoma 2 Glioma 2 Glioblastoma 2 Ependymoma 2 Carcinoma, Merkel Cell 2 Carcinoma, Medullary 2 Stomach Neoplasms 1 Somatostatinoma 1 Somatostatin Receptor-positive Neuroendocrine Tumor 1 Somatostatin Receptor-positive GEP-NET 1 Small Cell Lung Carcinoma 1 Serotonin Syndrome 1 Sarcoma, Synovial 1 Recurrence 1 Pituitary Neoplasms 1 Parathyroid Neoplasms 1 Pancreatic Diseases 1

Interventions

Lenalidomide 4 Gemcitabine 4 Dexamethasone 4 Cyclophosphamide 4 Bortezomib 4 Nivolumab 3 Cisplatin 3 Carboplatin 3 vandetanib 2 tumor necrosis factor-alpha, CNGRC fusion protein, human 2 pomalidomide 2 pembrolizumab 2 liposomal doxorubicin 2 fludarabine 2 durvalumab 2 capivasertib 2 Radiosurgery 2 Paclitaxel 2 Doxorubicin 2 Bevacizumab 2 Anthropogenic Effects 2 venetoclax 1 umbralisib 1 ublituximab 1 tremelimumab 1 tivozanib 1 ricolinostat 1 regorafenib 1 pazopanib 1 niraparib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Disease Progression × lutetium Lu 177 dotatate × Clear all

NCT04954820 2026-06-04

ReLUTH

Institut du Cancer de Montpellier - Val d'Aurelle

Phase 2 Recruiting

Neuroendocrine Tumors, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon ⚡